Although both polyomavirus infection and T cell-mediated rejection (TCMR) are characterized by tubulointerstitial inflammation in the renal allograft, these conditions are treated with opposing therapeutic regimens. To gain more insight into the differences between antiviral and alloimmune responses, we performed a case-control study, in which we immunophenotyped the inflammatory infiltrates in renal biopsy specimens with BK polyomavirus-associated nephropathy (BKPyVAN) and specimens with TCMR. Compared with TCMR, BKPyVAN was diagnosed later after transplantation; therefore, BKPyVAN specimens showed more chronic damage than TCMR specimens. However, TCMR and BKPyVAN specimens had 
Introduction
Current immunosuppressive treatment has improved renal allograft survival, albeit at the expense of reduced immune surveillance to pathogens. Consequently, the incidence of viral infections in renal transplant recipients has increased (Marcen, 2009 ). In the last decade, BK polyomavirus-associated nephropathy (BKPyVAN) has become an important cause of renal transplant morbidity, leading to graft loss in 40%-60% of infected patients (Ramos et al., 2009 ). The diagnosis is generally made by renal allograft biopsy and can sometimes be difficult because of the light microscopic similarities with T cell-mediated rejection (TCMR). Both BKPyVAN and TCMR are characterized by tubulointerstitial inflammation in the renal allograft (Ahuja et al., 2001) . The role of viral infections and their associated cellular infiltrates in the development of (chronic) allograft lesions is still incompletely understood and controversial. Previous studies have determined the phenotype of the cellular infiltrates in BKPyVAN compared with TCMR. Some studies reported the presence of more B lymphocytes in BKPyVAN (Ahuja et al., 2001; Latif et al., 2007; Li et al., 2013; Mannon et al., 2005) , whereas others found no differences in the amount of T and B cells (Rogers et al., 2009) . Buettner et al. showed a higher number of plasma cells in BKPyVAN compared with TCMR (Buettner et al., 2012) . The demonstration of lymphocytic infiltrates, marked tubulitis, and tubular HLA-DR expression in areas lacking polyomavirus replication may support the diagnosis of TCMR as proposed by Nickeleit et al. (Nickeleit et al., 2000) ; however, the former two criteria are often observed in BKPyVAN as well and therefore, cannot be considered pathognomic (Masutani et al., 2012; Menter et al., 2013) . A newly appreciated feature of BKPyVAN is that it may cause immunecomplex deposition along the tubular basement membrane. Granular staining of IgG, C3, and C4d is focally present on immunofluorescence accompanied by amorphous electrondense deposits on electron microscopy (Batal et al., 2009; Bracamonte et al., 2007) .
Of special interest is also the dendritic cell (DC) dynamics in the kidney (Rogers et al., 2014) . DC subsets have been shown to increase during renal damage (rejection and IgA nephropathy) (Woltman et al., 2007) , whereas during BKPyVAN, peripheral blood DCs were shown to decrease (Womer et al., 2010) ; however, back-to-back comparison of biopsy material of BKPyVAN and TCMR is currently lacking.
CHAPTER 10
The aim of this study was to investigate the demographic, clinical, histologic, and in particular, immunophenotypical differences between BKPyVAN and TCMR in a case-control setting.
Materials & Methods

Renal allograft recipients
All patients with a biopsy-proven BKPyVAN diagnosed between the years 2002 and 2010 and meeting the threshold for a minimal adequate specimen according to the Banff classification (at least seven glomeruli and one artery) were included (n=28). All biopsies were taken on clinical indication. The diagnosis of BKPyVAN was made on renal biopsies with patchy interstitial mononuclear inflammatory cell infiltrates in areas with necrotic tubular epithelium, homogenous intranuclear inclusion bodies (Ramaswami et al., 2011) and positive immunohistochemistry with an anti-SV40 antibody (EMD Millipore, Billerica, MA). After revision, biopsies from six patients were considered to have both BKPyVAN and TCMR (inflammation in areas without viral inclu-sions), resulting in 22 patients with pure BKPyVAN. For all patients, the biopsy described in this study was the first episode of graft dysfunction that needed a renal transplant biopsy. These patients had also not experienced an episode of rejection before BKPyVAN. All follow-up biopsies and the reason of graft failure in this group were investigated. For comparison, we used a cohort of 37 patients from the same time period of transplantation with biopsy-proven TCMR. We performed SV40 staining on these biopsies to exclude concomitant BKPyVAN. For all patients, data on DSAs at time of biopsy was available: 56 of 59 had measurements by complement-dependent cytotoxicity assay (CDC), three of 59 had only DSAs measured by Luminex single-bead assay, and 11 of 59 had both CDC and Luminex data available. coexpressed BDCA-1, except for mDCs, indicating its specific nature.
Histopathologic examination and immunophenotypical quantification
All biopsies were scored according to the last revised version of the Banff classification by two observers in a simultaneous manner (Haas et al., 2014) . Table 1 .
Statistical analyses
Differences in baseline demographic, clinical, and (immuno)histochemical parameters were evaluated with Fisher exact tests (binary and ordinal data) and Mann-Whitney rank tests (continuous data) where applicable. A Holm-Bonferroni correction of the P value was applied where indicated. We considered the missing staining as missing completely at random, because diagnostic processing was considered the sole reason for unavailability of biopsy material. We next performed multiple imputations of the data (M=10 datasets; maximum of 5 iterations). Numeric data were generated by predictive mean matching, binary data by logistic regression, and ordered data by proportional odds models. Univariable and multivariable logistic regression models were generated for the complete patients as well as on the M=10 imputed datasets that include all patients after imputation.
In case of logistic regression on the imputed datasets, the covariance matrices were used to pool the individual dataset estimates and obtain adjusted 95% CIs.
Data extracted from the M=10 datasets were pooled according to the rules by Rubin (Rubin, 1987) . Statistical analyses were performed using the R Computing Environment (version 2.15.2 for Macintosh). Graphs were created with use of the package ggplot2, version 1.0.0 for Macintosh. Two-tailed P values of <0.05 were considered significant.
Results
Demographic and clinical comparison between BKPyVAN and TCMR
We compared demographic and clinical parameters between patients with the diagnosis of BKPyVAN and patients with the diagnosis of TCMR. Patient characteristics are described in 
Histologic comparison between BKPyVAN and TCMR
We analyzed the acute and chronic Banff scores ( No significantly different HLA-DR staining was observed between BKPyVAN and TCMR. Univariable analyses on both complete patients and the M=10 imputed datasets showed more BDCA-1 + mDCs and fewer T cells in BKPyVAN (Table 2) .
DC-SIGN + mDC counts were also higher in BKPyVAN, but the OR was lower than for BDCA-1 + mDCs (OR, 1.10; 95% CI, 0.99 to 1.22; P=0.08). Figure 3 is the quantitative representation of Figure 2 and patients with a protocol biopsy free of rejection at the same time after transplantation and a group of 6 reperfusion biopsies (n=6) as a negative control. Figure 4 shows the BDCA-1 + cell counts in these sets of biopsies. In the protocol biopsies at reperfusion and after transplantation, there was hardly any BDCA-1 + cells visible.
The initial group of TCMR (n=37) Table 2 .
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Table 2 | Univariable comparison of inflammatory infiltrates in BKPyVAN versus TCMR
OR = odds ratio, CI = confidence interval. Here, the OR means that per increase in cell/HPF, the relative odds of having BKPyVAN is higher than having TCMR. 
Patients with features of both BKPyVAN and TCMR have similar BDCA-1 + cell counts as patients with BKPyVAN
We encountered 6 patients who had signs of BKPyVAN as well as TCMR in the same biopsy (tubulitis in areas without viral inclusions). When we analyzed 6 patients, these patients had comparable absolute (P=0.11) and relative (P=0.43 corrected for total inflammation) BDCA-1 + mDC counts as 22 patients with only BKPyVAN but had significantly higher absolute and relative BDCA-1 + mDC counts than patients with only TCMR (both P=0.03). These analyses suggest that these 6 patients might have BKPyVAN rather than TCMR. On the basis of BDCA-1 cell counts, we cannot exclude that additional alloimmune responses take place in these six patients.
The burden of tubulointerstitial inflammation correlates to BDCA-1
+ mDCs in BKPyVAN but not in TCMR
In the BKPyVAN patients, the amount of BDCA-1 + mDCs was associated with the for trend, respectively) did not show significant differences among the stages. In patients with TCMR, no association between the number of BDCA-1 + mDCs and the degree of tubulointerstitial inflammation was observed (P=0.84 with ti score and P=0.59 with t score).
Discussion
In this study, we show that the inflammatory infiltrates during an episode of BKPyVAN were enriched with BDCA-1+ mDCs compared with the inflammatory infiltrates during TCMR. These cells were found in close proximity of tubules that expressed the SV40 large T antigen.
It is generally thought that the inflammation in BKPyVAN is because of an appropriate antiviral-specific immune response and therefore, reduction of the immunosuppression is the gold standard strategy to date (Schaub et al., 2010) . However, the distinction between TCMR and BKPyVAN is difficult, and this is particularly important, because treatments are opposite. The major aim of this study was to compare the inflammatory infiltrates in renal biopsies during TCMR and BKPyVAN to get more insight in the specificity of the antiviral and alloimmune responses. We showed that the composition of the inflammatory infiltrates is different between BKPyVAN and TCMR, although the total burden of tubulointerstitial inflammation in the biopsies was similar. We observed an enrichment of BDCA-1 + mDCs in BKPyVAN in proportion to the total burden of tubulointerstitial inflammation, which was not the case during TCMR. BDCA-1 + mDCs were mainly but not exclusively localized in BKPyVAN in proportion to the total burden of tubulointerstitial inflammation, which was not the case during TCMR. BKPyVAN (Ahuja et al., 2001; Buettner et al., 2012; Kemény et al., 2010; Mannon et al., 2005) , whereas other studies did not find any differences in cell counts (Meehan et al., 2005; Rogers et al., 2009) . In our study, we show that the amount of T cells (in multivariable analyses), B cells, and plasma cells is comparable during BKPyVAN and TCMR as well as after we corrected the cell counts for the degree of total inflammation in the biopsy.
Tubular HLA-DR expression has been shown to be present during acute rejection but absent during BKPyVAN and was suggested as a discriminative factor (Nickeleit et al., 2000) . However, recent studies showed that, in some of the patients with BKPyVAN, HLA-DR expression is also present (Li et al., 2013; Menter et al., 2013) .
Our study is in line with these recent publications. It is known that HLA-DR expression can stimulate an allogeneic lymphocytic reaction and enhance T cell-mediated lysis (Rosenberg and Singer, 1992) . Thus, polyomavirus infection could possibly trigger an alloimmune response by inducing HLA-DR upregulation as previously proposed for CMV (von Willebrand et al., 1986) . Likewise, the polyomavirus BK large T antigen-derived peptide can elicit an HLA-DR promiscuous and polyfunctional CD4 + T cell response (Ramaswami et al., 2011) .
This study has some limitations. First, during our study period, only since 2008, regular peripheral blood and urine checks for BK polyomavirus replication were
introduced. This means that we could have missed patients who have active viremia, which would increase the yearly incidence of BKPyVAN in this period.
We are, therefore, also unable to investigate the association between peripheral blood DC subsets, BK polyomavirus replication, and our biopsy results. Second, because we did not include all episodes of TCMR during the study period, the predictive value for the BDCA-1 + mDCs could not be calculated. Calculation of the predictive value for novel markers to distinguish between antiviral and alloimmune response and therefore, aid in the decision to either decrease or increase immunosuppressive treatment is problematic because of the lack of a true gold standard diagnostic criterion. Third, we were unable to fully address the influence of time after transplantation on our results. A prospective approach to associate peripheral blood viral dynamics, biopsy results, and outcomes after standardized therapy should resolve this possible inclusion bias.
In conclusion, in these cohorts of biopsies, BKPyVAN and TCMR showed a similar degree of tubulointerstitial inflammation, and the composition of the infiltrates was overall very comparable between the 2 entities. We observed an increased amount of BDCA-1 + mDCs during BKPyVAN that was associated with the total burden of tubulointerstitial inflammation in patients with BKPyVAN but not in patients with TCMR, and these cells were mostly found in close proximity of BK polyomavirusinfected tubules. Our data suggest that particular differences in immune cell infiltration are present between BKPyVAN and TCMR and that these differences may underlie the immune responses characteristic for both entities.
